Single-Dose Anti-PD-1 Therapy Helps Predict Outcomes in Resectable Melanoma
Pathological response and immunological analyses can be used to predict clinical outcomes among patients with high-risk, resectable, stage III/IV melanoma who have had a single dose of neoadjuvant anti-PD1 therapy, a recent study shows (Nat Med. 2019;25[3]:454-461).
“Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks,” explained lead investigator Alexander C. Huang, MD, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, and colleagues.
“It is unclear, however, whether these early blood-based observations translate to the tumor microenvironment,” they added.
Theorizing that it would be possible to detect immune reinvigoration related to disease-free survival in the tumor at 3 weeks, Dr Huang and colleagues conducted a study of adjuvant/neoadjuvant anti–PD-1 therapy in patients with stage III/IV melanoma.
Findings demonstrated a rapid and potent anti-tumor response, with 8 of 27 patients having complete or major pathological responses after a single dose of anti–PD-1 therapy; all of these patients are still disease-free.
Dr Huang and colleagues reported that there was a link between these rapid pathologic and clinical responses and accumulation of exhausted CD8 T cells in the tumor at 3 weeks, with blood reinvigoration at as early as 1 week.
Of note, transcriptional analysis ahowed a pretreatment immune signature (ie, a neoadjuvant response signature) related to clinical benefit.
Alternatively, mechanisms of resistance (eg, immune suppression, mutational escape, and/or tumor evolution) were observed in patients with disease recurrence.
“Neoadjuvant anti-PD-1 treatment is effective in high-risk resectable stage III/IV melanoma,” Dr Huang and colleagues said.
“Pathological response and immunological analyses after a single neoadjuvant dose can be used to predict clinical outcome and to dissect underlying mechanisms in checkpoint blockade,” they concluded.—Hina Khaliq


